The proportion of patients developing myelogenous or lymphoblastic leukemia, or myelodysplastic syndrome, ranges from less than 10% in ANKRD26-RT to about 25% and 33% in ETV6-related thrombocytopenia (ETV6-RT) and in Familial platelet disorder with propensity to acute myelogenous leukemia (FDP/AML), respectively [12,13,37,38,39,40,41,42]. Here, ETV6 is linked to myelodysplastic syndrome.